Overview
The provided abstracts do not specifically define or address "Malignant multiple sclerosis" 12. General multiple sclerosis (MS) guidelines classify MS into subcategories and provide treatment recommendations 1.Management
Autologous hematopoietic stem cell transplantation (HSCT) may be offered to patients who fail one high-efficacy disease-modifying treatment (DMT) 1.
Early switching of DMT is recommended for unambiguous disease activity and for those with progression independent of relapses 1.
Guidelines address the management of MS in the context of coexisting cancer, including screening before or after initiating DMT, recommended follow-up for cancer in patients receiving DMT, and potential reintroduction of DMT after initial cancer treatment 2.Special Populations
Guidance is available for DMT choices in pregnancy, lactation, and pediatric MS 1.
For persons with MS over 50 years, who are more susceptible to cancer, recommendations address cancer screening and management, especially given the frequent use of immunosuppressive drugs 2.Key Recommendations
Autologous hematopoietic stem cell transplantation can be offered to patients who fail one high efficacy disease-modifying treatment (DMT) 1. (Evidence: Expert opinion)
Early switching of DMT is recommended for unambiguous disease activity and for those with progression independent of relapses 1. (Evidence: Expert opinion)
A strategic approach is recommended for managing cancer risk in persons with MS, encompassing screening before or after DMT initiation, appropriate MS management in the context of cancer, recommended cancer follow-up for patients on DMT, and potential reintroduction of DMT post-cancer treatment 2. (Evidence: Expert opinion)References
1 Jacob A, Shatila AO, Inshasi J, Massouh J, Mir R, Noori S et al.. Disease modifying treatment guidelines for multiple sclerosis in the United Arab Emirates. Multiple sclerosis and related disorders 2024. link
2 Collongues N, Durand-Dubief F, Lebrun-Frenay C, Audoin B, Ayrignac X, Bensa C et al.. Cancer and multiple sclerosis: 2023 recommendations from the French Multiple Sclerosis Society. Multiple sclerosis (Houndmills, Basingstoke, England) 2024. link